Veracyte Inc (VCYT) FinancialsVCYTVeracyte Inc

Evaluating the bottom line, Veracyte, Inc. maintains a gross margin of 71.93%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.29%, while the net margin is 16.96%. These profitability ratios, combined with a Return on Equity (ROE) of 8.77%, provide a clear picture of how effectively VCYT converts its operational activities into shareholder value.

In the context of the broader market, VCYT competes directly with industry leaders such as IRTC and CDNA. With a market capitalization of $3.64B, it holds a leading position in the sector. When comparing efficiency, VCYT's gross margin of 71.93% stands against IRTC's 72.80% and CDNA's 73.50%. Such benchmarking helps identify whether Veracyte, Inc. is trading at a premium or discount relative to its financial performance.

Veracyte has shown strong revenue growth with Q2 2026 revenue at $150.32 million and a gross margin of 71.93%, indicating solid profitability.